AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings
17/5 17:49
(RTTNews) - The US Food and Drug Administration approved AstraZeneca (AZN) and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11...